Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | bempikibart | Alopecia areata | Phase 2 | intravenous | Immunology | |
| Amgen Inc. | AMG 104 (AZD8630) | healthy volunteers and patients with asthma | Phase 2 | Trial Planned | Intravenous | Respiratory |
| Amgen Inc. | Avacopan (CCX168) - (ACCOLADE) | C3 glomerulopathy (C3G) | Phase 2 | Oral | #N/A | |
| Amgen Inc. | Daxdilimab (HZN-7734) | Discoid lupus erythematosus | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | Tezepelumab - SOURCE | Oral corticosteroid dependent asthma. | Phase 3 | Subcutaneous | Respiratory | |
| Amgen Inc. | TEZSPIRE | Chronic rhinosinusitis with nasal polyps | Phase 3 | Enrollment Conclusion | Subcutaneous | Respiratory |
| Amgen Inc. | TAVNEOS with Rituximab or a cyclophosphamide-containing regimen | Active ANCA-associated vasculitis | Phase 3 | Enrollment Initiation | Oral | Immunosuppressant |
| Amgen Inc. | TEPEZZA (Teprotumumab) | Thyroid Eye Disease (TED) - chronic | Phase 3 | Intravenous | Opthalmic |
